DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mu

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2 NSCLC.

Related Keywords

Edwards Kim , Trastuzumab Deruxtecan , , Evolving Treatment Landscape , First Line Trastuzumab Deruxtecan , Non Small Cell Lung Cancer , Nsclc , Her2 Nsclc , Her2 Mutated Nsclc , Her2 Non Small Cell Lung Cancer , Sadc , Antibody Drug Conjugates , T Dxd , Destiny Lung04 ,